No reports of adverse events related to the recall have been reported
TUESDAY, Nov. 3, 2020 (HealthDay News) — A cancer-causing compound in the drug metformin has resulted in the recall of two lots of the drug.
Kansas City-based Nostrum Laboratories Inc., said Monday that it is voluntarily recalling its metformin HCl extended release tablets, USP 750 mg, according to a notice from the U.S. Food and Drug Administration. No reports of adverse events related to the recall have been reported, the company said.
These tablets are tainted with higher-than-safe levels of the chemical nitrosamine, or NDMA. NDMA is a possible carcinogen, according to the U.S. Environmental Protection Agency.
The affected product is packaged in HDPE bottles of 100 tablets, under NDC 29033-056-01. The affected Metformin HCl Extended Release Tablets, USP 750 mg lots are under NDC 29033-056-01, lot numbers MET200101 and MET200301, with the expiration date 05/2022. It can be identified as an off-white oblong tablet debossed with “NM7.”
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer 
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status 
December 2024 to 2025 Saw Significant Increase in Leucovorin Dispensing 
Dose-Dependent Link Seen for Clomiphene Citrate, Adverse Perinatal Outcomes 
Dexrazoxane Offers Lasting Doxorubicin Cardioprotective Effect in Childhood Cancer Survivors 
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings 
Many With Atypical Alzheimer Disease Do Not Qualify for Anti-Amyloid Therapy 
Effect of Preparation Techniques Before Embryo Transfer Appears to Be Limited 
